PMID- 21370139
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121002
LR  - 20110303
IS  - 1543-1894 (Print)
IS  - 1543-1894 (Linking)
VI  - 49
DP  - 2001
TI  - Detection of t(14; 18)(q32;q21)-Associated BCL-2/J(H) Gene Fusion in Non-Hodgkin 
      Lymphoma.
PG  - 147-63
LID - 10.1385/1-59259-081-0:147 [doi]
AB  - The identification and study of nonrandom recurrent chromosomal translocations 
      has substantially increased our understanding of the non-Hodgkin lymphomas. 
      Cytogenetic and molecular genetic data now form an integral part of current 
      lymphoma classifications (1) and provide important information for diagnosis, 
      tumor biology, and in some cases prognosis. The t(14;18)(q32;q21) abnormality is 
      the most common translocation detected in B-lineage lymphoma and results in 
      juxtaposition of the BCL-2 gene (18q21) and the JH locus of the immunoglobulin 
      (Ig) heavy chain gene (14q32) (2-5). More specifically, in the North American 
      population, alterations of the BCL-2 gene are detected in approx 75 to 85% of 
      low-grade follicular lymphomas, 20-30% of aggressive large B-cell lymphomas, and 
      rarely in other B-cell tumors (e.g., chronic lymphocytic leukemia (CLL), acute 
      lymphoblastic leukemia) (2,6-9). As a consequence of the BCL-2/JH fusion, 
      deregulated overexpression of the antiapoptotic bcl-2 protein occurs owing to 
      constitutive transcriptional activation of the BCL-2 gene by the Ig heavy chain 
      gene enhancer. The unbridled expression of bcl-2 protein in lymphoid tumors 
      confers resistance to programmed cell death (10,11) and is implicated in primary 
      therapeutic failure and a less favorable prognosis (12-14). Although karyotypic 
      detection of lymphoma-associated translocations such as the t(14;18) has proved 
      to be useful in disease diagnosis and subcategorization, molecular genetic 
      approaches including polymerase chain reaction (PCR) and fluorescence in situ 
      hybridization (FISH) have gained substantial popularity owing to their rapidity, 
      relatively low cost, and increased sensitivity (6,15-22).
FAU - Viswanatha, D S
AU  - Viswanatha DS
AD  - Departnmnt ofPathology, Universily of New Mexico Health Science Center, 
      Albuquerque, NM.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Methods Mol Med
JT  - Methods in molecular medicine
JID - 101123138
EDAT- 2001/01/01 00:00
MHDA- 2001/01/01 00:01
CRDT- 2011/03/04 06:00
PHST- 2011/03/04 06:00 [entrez]
PHST- 2001/01/01 00:00 [pubmed]
PHST- 2001/01/01 00:01 [medline]
AID - 10.1385/1-59259-081-0:147 [doi]
PST - ppublish
SO  - Methods Mol Med. 2001;49:147-63. doi: 10.1385/1-59259-081-0:147.